Commentary
he field of NAFLD and its progressive form, NASH, has, despite the challenges of the COVID-19 pandemic, continued to rapidly evolve in 2020. There have been substantial advances in NAFLD mechanisms, diagnostics, and treatment.
Key developments include the identification of a multiparametric cellular and tissue signature to define disease progression and new insights into the definition of disease progression and advancements in non-invasive diagnostics. The FibroScan-AST (FAST) score non- invasively identifies patients at risk of progressive NASH for clinical trials and potentially in clinical practice.
Hepatic inflammatory responses in liver fibrosis